Posted by Michael Wonder on 22 Oct 2021
Oncopeptides withdraws Pepaxto in US, scale down organisation and focus on R&D
22 October 2021 - Oncopeptides today announces that the company has decided to withdraw Pepaxto (melphalan flufenamide) from the market in the US, following the Phase 3 OCEAN trial, which showed an overall survival in the ITT population with a hazard ratio of 1.104.
The decision has been made after interactions and dialogue with the US FDA.
